Ahmet YILMAZ, Zafer PEKKOLAY, Alpaslan Kemal TUZCU, Nevzat GÖZEL, Yaşar YILDIRIM, Faruk KILINÇ, Fatih ŞAHPAZ, Hikmet SOYLU

Akromegali hastalarının metabolik özelliklerinin değerlendirilmesi

Amaç: Akromegali aşırı miktarda büyüme hormonu (BH) ve insülin benzeri büyüme faktörü (IGF-1) salınımı ile karakterize bir sendromdur. Bu çalışmada, kliniğimizde akromegali tanısı ile takip edilen hastalarda tespit edilen metabolik bozuklukların paylaşılması amaçlanmıştır. Yöntemler: Çalışmamıza 2010 ile 2015 yılları arasında polikliniğimizde akromegali tanısıyla izlenen 105 hasta alındı. Hastaların yaş, cinsiyet, tutulum özelliği, ek sistemik ve metabolik hastalıkları ve laboratuvar bulguları retrospektif olarak kaydedildi. Bulgular: Çalışmaya alınan 105 hastanın 56'sı kadın (%53,3), 49'u erkek (%46,7) idi. Hastaların yaşları 23-78 yıl (ortalama 42,1±16,7) arasındaydı. Hastaların 34'ünde (%32,3) hipertansiyon, 20'sinde (%19,04) diyabetes mellitus, ve 11'inde (%10,4) bozulmuş glukoz toleransı saptandı.Sonuç: Somatik bozukluklar (el ve ayaklarda büyüme gibi) hastalığın ana özelliğidir ancak prognozu belirleyen kardiyovasküler, respiratuvar ve metabolik komplikasyonlardır. Akromegalide hipertansiyon ve diyabet sıktır, kardiyovasküler hastalıklar ölüm nedenleri arasında ilk sıradadır. Çalışmamızın bu açıdan ülkemize ait verilerin oluşmasına katkıda bulunacağını düşünmekteyiz.

Evaluation of the metabolic characteristics of patients with Acromegaly

Objective: Acromegaly is a syndrome characterized by growth hormone (GH) and insulin like growth factor-1 (IGF-1) over secretion. It was aimed to sharing detected metabolic disorders of the patients with acromegaly who have been under follow-up at our clinic. Methods: One hundred five patients, who were diagnosed as acromegaly in our clinic between 2010 and 2015, were enrolled to the study. The age, gender, involvement feature additional systemic and metabolic diseases were recorded and laboratory findings.Results: A total of 105 patients included in the study, 56 women (53.3%) and 49 men (46.7%), respectively. Patient's' ages ranged 23-78 (mean 42.1±16.7). 34 patients (32.3%), hypertension in 20 (19.04%), diabetes mellitus, and is 11 (10.4%) had impaired glucose tolerance.Conclusion: Somatic disfigurement (hand and foot enlargement etc.) is the major characteristic of the disease but the prognosis is determined by cardiovascular, respiratory and metabolic complications. In acromegaly, hypertension and diabetes are common, cardiovascular disease is the principal cause of death. We believe that our study will contribute to the determination of our country's data.

PDF

___

Melmed S. Medical progress: Acromegaly. N Engl J Med 2006;355:2558-2565.
Thorner MO, LeeVance M, Laws ER Jr, et al. The ante- rior pituitary. W Textbook of Endocrinol 1998;128:249- 340.
Acromegaly: Epidemiology, etiology and classification in: Acromegaly and its management In: Haris AG. Lipp Raven NY 1996;22:17-20.
Ho KY, WeisSberger AJ. Characterisation of 24 hour GH secretion in acromegaly: Implications for diagno- sis and therapy. Clin Endocrinol 1994;41:75-83.
Baumann G. Growth hormone and its disorders. I: Prin- ciples and Practices of Endocrinology and Metabo- lism, In: Becker KL, ed. Lipincott Williams & Wilkins 2001;20:129-145.
Melmed S. Acromegaly. NEJM 1990;322:966-977.
Barkan AL, Burman P, Clemmons DR, et al. Glucose homeostasis and safety in patients with acromegaly converted from long-acting octreotide to pegvisomant. J Clin Endocrinol Metab 2005;90:5684-5691.
Parkinson C, Drake WM, Wieringa G, et al. Serum lipo- protein changes following IGF-1 normalization using a growth hormone receptor antagonist in acromegaly. Clin Endocrinol 2002;56:303-311.
Tan KC, Shiu SW, Janus ED, et al. Subfractions in ac- romegaly: relation to growth hormone and insulin-like growth factor-I. Atherosclerosis 1997;129:59-65.
Colao A, Marzullo P, Ferone D, et al. Cardiovascular effects of depot longacting somatostatin analog Sand- ostatin LAR in acromegaly. J Clin Endocrinol Metab 2000;85:3132-3140.
Colao A, Vitale G, Pivonello R, et al. The heart: an end-organ of GH action. Eur J Endocrinol 2004;15:93- 101.
Mestron A, Webb SM, Astorga R, et al. Epidemiol- ogy, clinical characteristics, outcome, morbidity and mortality in acromegaly based on the Spanish Acro- megaly Registry (Registro Espanol de Acromegalia, REA). Eur J Endocrinol 2004;151:439-446.
Hekimsoy Z, Özmen B. Acromegali. Turk J Endocrinol Metabol 2003;7:69-75.
Chen YL, Wei CP, Lee CC, Chang TC. Diabetic keto- acidosis in a patient with acromegaly. J Formos Med Assoc 2007;106:788-791.
Smith TR, Elmendorf JS, David TS. Growth hor- mone-induced insulin resistance: role of the insulin receptor, IRS-1, GLUT-1, and GLUT-4. Am J Physiol 1997;272:1071-1080.
Hekimsoy Z, Ozmen B, Ulusoy S. Homocysteine levels in acromegaly patients. Neuro Endocrinol Lett 2005;26:811-814.
Ronconi V, Giacchetti G, Mariniello B, et al. Reduced nitric oxide levels in acromegaly: cardiovascular impli- cations. Blood Press 2005;14:227-232.
Absoch A, Tyrrell JB, Lamborn KR, et al. Transspho- nidal microsurgery for growth hormone-secreting pitu- itary adenomasinitial outcome and long-term results. J Clin Endocrinol Metab 1998;83:3411-3418.
Melmed S. Acromegaly and cancer: not a problem. J Clin Endocrinol Metab 2001;86:2929-2934.
Sacca AL, Cittadini A, Fazio S. Growth hormone and the heart. Endocrine Rev 1994;15:555-572.
Nabarro JDN. Acromegaly. Clin Endocrinol 1987;26:481-512.
Lam KS, Pang RW, Janus ED, et al. Serum apoli- poprotein (a) correlates with groth hormone levels in Chinese patients with acromegaly. Atherosclerosis 1993;104:183-188.